We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Eradication of established tumors in mice by a combination antibody-based therapy.
- Authors
Uno, Tomoyasu; Takeda, Kazuyoshi; Kojima, Yuko; Yoshizawa, Hirohisa; Akiba, Hisaya; Mittler, Robert S.; Gejyo, Fumitake; Okumura, Ko; Yagita, Hideo; Smyth, Mark J.
- Abstract
Tumor-cell apoptosis is the basis of many cancer therapies, and tumor-specific T cells are the principal effectors of successful antitumor immunotherapies. Here we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand (TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8+ T cells capable of eradicating preestablished tumors. Primary fibrosarcomas initiated with the carcinogen 3-methylcholanthrene (MCA), multiorgan metastases and a primary tumor containing as many as 90% tumor cells resistant to DR5-specific monoclonal antibody were rejected without apparent toxicity or induction of autoimmunity. This combination therapy of three monoclonal antibodies (trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon (IFN)-γ in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-γ in the tumor rejection process. These results in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an effective strategy for cancer immunotherapy in humans.*
- Subjects
IMMUNOTHERAPY; T cells; CANCER treatment; APOPTOSIS; MONOCLONAL antibodies
- Publication
Nature Medicine, 2006, Vol 12, Issue 6, p693
- ISSN
1078-8956
- Publication type
Article
- DOI
10.1038/nm1405